Claims for Patent: 7,306,799
✉ Email this page to a colleague
Summary for Patent: 7,306,799
Title: | Use of VEGF inhibitors for treatment of eye disorders |
Abstract: | Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy. |
Inventor(s): | Wiegand; Stanley J. (Croton on Hudson, NY), Papadopoulos; Nicholas J. (LaGrangeville, NY), Yancopoulos; George D. (Yorktown Heights, NY), Fandl; James P. (LaGrangeville, NY), Daly; Thomas J. (New City, NY) |
Assignee: | Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) |
Application Number: | 11/089,803 |
Patent Claims: | 1. A therapeutic method for treating or ameliorating an eye disorder, comprising administering a fusion polypeptide capable of binding vascular endothelial growth factor (VEGF) to a
patient in need thereof, wherein the fusion polypeptide consists of an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor Flt1 and Ig domain 3 of a second VEGF receptor Flk1 or Flt4; and a multimerizing component, wherein the multimerizing
component is an immunoglobulin domain or fragment of an immunoglobulin domain, wherein the eye disorder is selected from the group consisting of age related macular degeneration and diabetic retinopathy, and wherein administration is selected from the
group consisting of eye drops, subconjunctival injection, subconjunctival implant, intravitreal injection, intravitreal implant, sub-Tenon's injection, and sub-Tenon's implant.
2. The therapeutic method of claim 1, wherein the fusion polypeptide comprises SEQ ID NO:6. 3. A therapeutic method for treating or ameliorating an eye disorder, comprising administering a dimeric protein comprising two fusion polypeptides, wherein each fusion polypeptide consists of the amino acid sequence of SEQ ID NO:6, wherein the eye disorder is selected from the group consisting of age related macular degeneration and diabetic retinopathy, and wherein administration is selected from the group consisting of eye drops, subconjunctival injection, subconjunctival implant, intravitreal injection, intravitreal implant, sub-Tenon's injection, and sub-Tenon's implant. 4. A method for the treatment of a human subject diagnosed with age-related macular degeneration, comprising administering an effective amount of a vascular endothelial growth factor (VEGF) inhibitor to the human subject, the method comprising: (a) administering to the subject an initial dose of at least approximately 25-4000 micrograms VEGF inhibitor protein per eye; and (b) administering to the subject a plurality of subsequent doses of the VEGF inhibitor protein in an amount that is approximately the same or less than the initial dose, wherein the subsequent doses are separated in time from each other by at least two weeks, wherein the VEGF inhibitor is a dimeric protein comprising two fusion polypeptides, wherein each fusion polypeptide consists of an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor Flt1 and Ig domain 3 of a second VEGF receptor Flk1 or Flt4, and a multimerizing component, and wherein the multimerizing component is an immunoglobulin domain or fragment of an immunoglobulin domain, and wherein administration is selected from the group consiting of eye drops, subconjunctival injection, subconjunctival implant, intravitreal injection, intravitreal implant, sub-Tenon's injection, and sub-Tenon's implant. 5. The method of claim 4, wherein the initial dose is at least approximately 50 micrograms of VEGF inhibitor protein. 6. The method of claim 5, wherein the initial dose is at least approximately 100 micrograms of VEGF inhibitor protein. 7. The method of claim 6, wherein the initial dose is at least approximately 1000 micrograms of VEGF inhibitor protein. 8. The method of claim 4, wherein the subsequent doses are separated in time from each other by at least four weeks. 9. The method of claim 8, wherein the subsequent doses are separated in time from each other by at least 3 to 6 months. 10. The method of claim 4, wherein the initial dose and at least one subsequent dose is administered by intravitreal injection. 11. The method of claim 4, wherein the VEGF inhibitor is a dimer having two fusion polypeptides, wherein each fusion polypeptide comprises the amino acid sequence of SEQ ID NO:6. |
Details for Patent 7,306,799
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Regeneron Pharmaceuticals, Inc. | EYLEA | aflibercept | Injection | 125387 | November 18, 2011 | ⤷ Sign Up | 2039-03-29 |
Regeneron Pharmaceuticals, Inc. | EYLEA | aflibercept | Injection | 125387 | August 16, 2018 | ⤷ Sign Up | 2039-03-29 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 7,306,799
Country | Patent Number | Estimated Expiration |
---|---|---|
South Africa | 200600157 | ⤷ Sign Up |
South Africa | 200110068 | ⤷ Sign Up |
Yugoslavia | 86901 | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2005000895 | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 02060489 | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 0075319 | ⤷ Sign Up |
Uruguay | 28396 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.